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Morphine stimulates tumor angiogenesis and cancer progression in mice. We examined if morphine inﬂuences endothelial-
pericyte interaction via platelet-derived growth factor-BB (PDGF-BB) and PDGF receptor-β (PDGFR-β). Clinically relevant doses
of morphine stimulated PDGF-BB secretion from human umbilical vein endothelial cells and activated PDGFR-β and mitogen-
activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) phosphorylation in human pericytes. These in vitro
eﬀects of morphine were translated into promotion of tumor angiogenesis in a transgenic mice model of breast cancer when
treatedwithclinicallyuseddoseofmorphine.Increasedvessel-associatedimmunoreactivityofdesminandPDGFR-β wasobserved
on pericytes in tumors of morphine-treated mice. These data suggest that morphine potentiates endothelial-pericyte interaction
via PDGF-BB/PDGFR-β signaling and promotes tumor angiogenesis, pericyte recruitment, and coverage of tumor vessels. We
speculate that morphine may impair the eﬀectiveness of antiangiogenic therapy by inﬂuencing vascular pericyte coverage.
1.Introduction
Angiogenesis, sprouting of new blood vessels from the exist-
ing vessels, is critical for cancer progression and metastases
[1]. Endothelial cells, the building blocks of blood vessels,
and endothelial cell-speciﬁc cytokine vascular endothelial
growth factor (VEGF) and its receptors have therefore been
a target of anticancer therapies [2–4]. Several VEGF and
endothelial cell speciﬁc therapies are either in clinical use or
clinical trials. However, drug resistance and ineﬀectiveness
are a major challenge limiting the success of these promising
new drugs. Recent studies suggest that vasculature is not
merely an endothelial structure, rather it is closely associated
with mural cells including pericytes and vascular smooth
muscle cells (VSMCs) [5–7]. The exact role of pericyte
coverage of tumor vasculature is not clear, but paradoxical
roles are proposed that favor inhibition of angiogenesis on
one hand and a barrier to antiangiogenic therapy on the
other [4, 8, 9].
Pericyte coverage of the vascular endothelium is con-
trolled by several cytokines including the platelet-derived
growth factors (PDGFs) and VEGF [10, 11]. PDGF-BB sec-
reted by endothelial cells acts as an attractant to recruit
PDGFR-β-expressing pericytes and pericyte progenitor cells
to the endothelium [12]. In turn, pericytes provide guidance
to endothelial sprouts, scaﬀolding for the vasculature to
grow, and stabilize the vessel wall [5, 13, 14]. Thus, endoge-
nous and exogenous molecules that inﬂuence pericyte-endo-
thelial interaction may inﬂuence tumor angiogenesis and
interfere with therapies directed towards them. For example,
morphine stimulates the expression of PDGF-BB in hu-
man brain microvascular endothelial cells (HBMECs) [15]
and coactivates PDGFR-β signaling in the mouse retinal
microvascular endothelial (mREC) and mesangial cells (spe-
cialized mural cells) in the kidney [16, 17].
Morphine used in clinically relevant doses promotes an-
giogenesis in vitro and in vivo and increases vascular per-
meability [18–20]. This proangiogenic activity of morphine
is translated into promotion of breast and lung cancer in
mice [18, 19, 21]. Additionally, morphine promotes breast
and lung cancer cell proliferation and migration. Opioid2 Journal of Oncology
receptors (ORs) particularly mu opioid receptor (MOR)
mediate the analgesic eﬀect of morphine and are highly
e x p r e s s e di nh u m a nl u n gc a n c e r[ 21–23]. Morphine and its
congeners are used to treat pain due to cancer, particularly
in the advanced stages of malignancy when most of the
therapies are ineﬀective. It is likely that morphine inﬂuences
endothelial-pericyte interaction and may further contribute
to ineﬀectiveness of targeted therapies.
Therefore, we examined morphine-induced endothelial
and pericyte-speciﬁc activity mediated by PDGF-BB/
PDGFR-β signaling. We used primary human umbilical vein
endothelial cells (HUVECs) and human placenta-derived
pericytes for in vitro studies and a transgenic mouse model
of breast cancer, which mimics the evolutionary spectrum
of human disease. We found that morphine stimulates
PDGF-BB secretion by HUVEC and phosphorylation of
PDGFR-β, mitogen-activated protein kinase/extracellular
signal-regulated kinase (MAPK/ERK), and signal transducer
and activator of transcription 3 (STAT3) in pericytes. Com-
plementary to these in vitro observations, morphine in cli-
nically used doses increased desmin- and PDGFRβ-positive
cellsinthetumorvasculatureofmice,suggestiveofincreased
proliferation and/or recruitment of vessel-associated peri-
cytes.
2.MaterialsandMethods
2.1. Tumor Model and Drug Treatments. Female transgenic
mice carrying a rat C3(1) simian virus 40 large tumor
antigen (C3TAG) fusion gene that develop highly invasive
breast tumors were used. Female C3TAG mice show the
evolutionary spectrum of human inﬁltrating ductal carci-
noma [24]. These mice develop ductal epithelial atypia at 8
weeks, progression to intraepithelial neoplasia at 12 weeks
(resembling human ductal carcinoma in situ), and invasive
carcinoma and grossly palpable tumors at 16 weeks. Tumors
predominantlymetastasizehematogenouslytothelungs,and
also to the liver, adrenals, and heart. By 6 months of age, all
the mice die because of universal development of multifocal
mammary adenocarcinomas. We have used this model in
previous studies to target tumor angiogenesis using blood
outgrowth endothelial cells expressing sFlt1 [25]. Three-
month-old C3TAG mice were subcutaneously injected with
morphine sulfate (Baxter Esilerderle Healthcare, Cherry Hill,
NJ) at 0.5mg/Kg/d for 2wks and the dose escalated every
two weeks to 0.75mg/Kg/d, 1.0mg/Kg/d, 1.25mg/Kg/d, and
1.5mg/Kg/d, or with PBS, for a period of seven weeks. All
reagents were from Sigma-Aldrich, St. Louis, MO, unless
speciﬁed.
2.2. HUVEC Culture. Human umbilical vascular endothelial
cells (HUVECs) were isolated from umbilical cords and cul-
tured as previously described [26]. Complete HUVEC
culture medium (CHCM) consisted of medium 199 (Life
Technologies, Inc., Gaithersburg, MD), 40μg/mL heparin
sodium salt, 15% fetal bovine serum, 2.4% 200mM L-
glutamine, 100units/mL penicillin, 100units/mL streptom-
ycin, 100units/mL fungizone, 0.04% freshly thawed ENDO-
GRO,and0.1%sodiumpyruvate.PrimaryHUVECsbetween
passages one and three were used for all experiments.
HUVECs were cultured in serum and growth factor-free
medium(SFM)toexaminetheeﬀectofmorphineonPDGF-
BB expression and for signaling studies. SFM consisted of
medium MCDB 131 (Life Technologies, Inc., Gaithers-
burg, MD), dibutyryl cAMP, heparin, L-glutamine, Pen/
Strep/Fungizone, and hydrocortisone as described [18].
2.3. Pericyte Culture. Human pericytes from placenta were
purchased from PromoCell (PromoCell, Heidelberg, Ger-
many) and cultivated per the manufacturer’s instructions in
pericyte growth medium. Pericytes were serum and growth
factor starved in pericyte serum and growth factor-free med-
ium (PSFM). PSFM consisted of medium 199 (Life Tech-
nologies, Inc., Gaithersburg, MD), 0.5% fetal bovine ser-
um, 100units/mL penicillin, 100units/mL streptomycin,
100units/mL fungizone, and 2mM L-Glutamine.
2.4. ELISA. HUVEC were serum and growth factor starved
in SFM overnight followed by incubation with diﬀerent con-
centrations of morphine indicated in the ﬁgures for an addi-
tional 48hrs. The supernatant from HUVEC was analyzed
for PDGF-BB using an ELISA Kit (RayBiotech, Norcross,
GA). Absorbance was read at 450nm using an ELISA reader
(Synergy HT, Winooski, VT). The concentration of PDGF-
BB in the supernatant was calculated using the standard
curve prepared in parallel with each experiment. SFM
cultured without HUVEC in parallel to the experiment was
used as a blank/negative control.
2.5. Western Blot Analysis. Pericytes were serum starved
overnightasdescribedandstimulatedwith0.1μMmorphine
or 20ng/mL of PDGF-BB. Cell lysates were prepared as des-
cribed by us earlier using a cocktail of protease inhibitors
[18]. Protein lysates containing 100μg of protein were sepa-
rated on a 3–15% gradient SDS-PAGE gel and then trans-
ferred to a polyvinylidene ﬂuoride membrane (Immobilon;
Millipore, Bedford, MA). Protein bands were detected using
1:250phospho-PDGFR-β(Upstate,LakePlacid,NY),1:500
PDGFR-β, 1:1000 phospho-STAT3, 1:1000 STAT3, 1:1000
phospho-MAPK/ERK, and 1:1000 MAPK/ERK (all from
Cell Signaling Technology, Danvers, MA). Alkaline phos-
phate-conjugated secondary antibodies (1:5000, Santa Cruz
Biotechnology,SantaCruz,CA)andECFsystem(Amersham
Bioscience, Buckinghamshire, UK) were used to detect
chemiluminescent signals on a Storm 860 Phosphorimager
(Molecular Dynamics, Sunnyvale, CA). Protein bands were
quantitated by densitometric analysis using ImageJ Software
(National Institutes of Health, Bethesda, MD).
2.6. Immunoﬂuorescent Staining. Tumors were frozen in
liquid nitrogen, embedded in optimal cutting temperature
compound (OCT), and cut into 6μM cryosections. Sections
were ﬁxed in 4% paraformaldehyde and immunostained
using the following primary antibodies at the indicated
dilutions: 1:100 rabbit anti-PDGFR-β (Upstate, Lake Placid,Journal of Oncology 3
NY);1:100mouseantismoothmuscleactin(α-SMA;Sigma,
St. Louis, MO); 1:50 goat antidesmin (Santa Cruz); 1:50
rat anti-CD31-FITC (BD Pharmingen, San Diego, CA).
Species-speciﬁc secondary antibodies conjugated with Cy3
or TRITC were used at the following dilutions: 1:400
donkey anti-rabbit IgG-Cy3 (Jackson Laboratories, West
Grove, PA) and 1:50 donkey anti-goat IgG-TRITC (Santa
Cruz). In addition, isotype-matched IgG was used as control
(Santa Cruz Biotechnology, Santa Cruz, CA). Fluorescent
images were visualized and obtained using an Olympus IX70
epiﬂuorescent microscope with an attached Olympus DP70
digital camera (Olympus America Inc., Center Valley, PA).
2.7. Quantitation of Immunoreactive Pixels and Tumor Angio-
genesis. Pericyte markers, desmin, α-SMA, and PDGFR-β,
were examined in relation to endothelial cell marker CD31.
Superimposed images were analyzed with Adobe Photoshop
tocalculatetheratioofdesmin,α-SMA,orPDGFR-β relative
to CD31-positive cells. Ratios were based on the ﬂuorescent
intensity of the proteins. For morphometric analysis of
tumor angiogenesis, CD31-positive images were binarized
and skeletonized using Adobe Photoshop and the Image
Processing Tool-Kit Plug-in Functions for Adobe Photoshop
(Reindeer Games, Asheville, NC), and total lengths, ends,
andnodesofvesselswerequantiﬁedasdescribedbyusearlier
[18].
2.8. Statistical Analysis. All data are expressed as mean
± SEM. All statistical analyses were performed using Prism
software (GraphPad Prism Inc., San Diego, CA). Signiﬁcance
was determined using unpaired, Student’s t-tests. P<0.05
was considered signiﬁcant.
3. Results
3.1. Morphine Stimulates PDGF-BB Secretion by HUVEC.
Morphine induces PDGF-BB expression in HBMECs [15],
b u tt h i sn e e d st ob es e c r e t e dt oh a v eap a r a c r i n ee ﬀect on
pericytes. We examined if PDGF-B was secreted into the
culture supernatants by HUVEC stimulated with morphine
for 48h. Morphine at the doses of 0.1 and 1μM stimulated
about a 2-fold increase in the secretion of PDGF-BB in the
culture medium as compared to PBS (Figure 1). However,
1mM concentration of morphine did not have a signiﬁcant
eﬀect on PDGF-BB secretion as compared to PBS. Phase
contrast microscopy and Trypan blue staining of HUVEC
incubated with 0.1 and 1μM morphine showed that more
than 99% cells were alive and appeared normal (data not
shown). In contrast, more than 99% of HUVECs were
dead after incubation with 1mM morphine. Morphine
concentrations at 0.1 and 1μM are consistent with the
observed plasma/serum concentration of diverse patient
population treated with morphine, which ranges between
2nM and 3.5mM [27, 28]. Earlier studies from our labo-
ratory demonstrated that 1mM morphine was cytotoxic to
human dermal microvascular endothelial cells (HDMECs)
[18]. Thus, clinically relevant concentration of morphine
stimulates PDGF-BB secretion from endothelial cells, a key
step in endothelial-pericyte interaction.
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Figure 1: Morphine stimulates PDGF-BB release from endothelial
cells. PDGF-BB was analyzed in the cell culture supernatants of
HUVEC incubated with diﬀerent concentrations of morphine or
PBS in serum- and growth factor-free medium for 48h at 37◦C.
In parallel, serum- and growth factor-free medium was incubated
in ﬂasks without cells to serve as blank. A dose-dependent increase
in PDGF-BB is seen between 0.1 and 1μM morphine, whereas no
statistically signiﬁcant increase occurred with 1mM morphine, as
compared to PBS. Each bar is the mean ± SEM of three separate ex-
periments from 3 diﬀerent cultures of HUVEC.
3.2. Morphine Activates PDGFR-β,M A P K / E R K ,a n dS t a t 3
Signaling in Pericytes. Proliferation, recruitment, and endo-
thelial interaction of pericytes with endothelium are depen-
dent upon PDGFR-β signaling. We observed that 0.1μM
morphineaswellas20ng/mLPDGF-BBstimulatessustained
activation of PDGFR-β phosphorylation on pericytes from
5min to 60min of incubation (Figures 2(a) and 2(b)). Inter-
estingly, both morphine and PDGF-BB signiﬁcantly stim-
ulated MAPK/ERK phosphorylation in a time-dependent
manner, which returned to baseline after 60min of incu-
bation. On the other hand, both morphine and PDGF-
BB stimulated the phosphorylation of STAT3, but it was
not statistically signiﬁcant. Therefore, both morphine and
PDGF-BB stimulate PDGFR-β and MAPK/ERK signaling in
pericytes.
3.3. Morphine Promotes Angiogenesis in Tumors of C3TAG
Mice. Three-month-old C3TAG mice bearing multiple
breast tumors, which grow spontaneously, were treated with
clinically relevant escalating dose of morphine, for seven
weeks. Multiple tumors in diﬀerent sizes were dissected out,
but only tumors about 1cm × 0.5cm were analyzed for
tumor angiogenesis (Figures 3(a)–3(d)). Morphometric
analysis was performed on tumor sections stained with anti-
CD31-FITC. Diﬀerent parameters of angiogenesis analyzed
included vessel density (a), total length of vessels (b), num-
berofvessels(ends,(c)),andbranching(nodes,(d)).Asigni-
ﬁcant increase was observed in each of these parameters in
morphine-treated mice as compared to PBS-treated mice.
Excessive branching (nodes) and increased number of vessels
is a typical feature of disorganized growth of vasculature in4 Journal of Oncology
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Figure 2: Morphine coactivates PDGFR-β phosphorylation and MAPK/ERK signaling in human pericytes. Human placenta-derived
pericytes were incubated with 0.1μM morphine or 20ng/mL PDGF-BB for indicated time or with PBS, followed by cell lysis using protease
inhibitors. Lysates containing 100μg protein were resolved on 3–15% SDS gel and Western blotted as described in the methods. (a)
Representative image of ﬁve diﬀerent Western blots for phospho- and total-PDGFR-β, MAPK/ERK, and STAT3 is shown. (b) Densitometric
analysis of protein bands is represented as a ratio of phospho- to total-protein for each protein. Each bar is the mean ± SEM of ﬁve diﬀerent
blots.
∗P < 0.01,
∗∗P < 0.001, for each time point compared to unstimulated in each graph.
tumors. Morphine, therefore, further augments tumor angi-
ogenesis.
3.4. Morphine Treatment Results in Increased Desmin Immu-
noreactivity but Does Not Inﬂuence α-SMA Immunoreactivity
in Tumors. Tumors from C3TAG mice treated with mor-
phine as described above were costained with anti-CD31-
FITC (green vasculature) and desmin (red) or with anti-
CD31-FITC (green) and α-SMA (red). Immunoﬂuorescent
images show a signiﬁcant increase in desmin immunoreac-
tivityinmorphinetreatedascomparedtoPBS-treatedmouse
tumors (Figure 4(a), top row). Most of the desmin staining
colocalized with CD31-postive endothelium in a random
fashion and showed a signiﬁcant increase with morphine
treatment as compared to PBS (Figure 4(b)). In some areas,
desmin staining is independent of CD31 staining (magenta
arrow in (a)). Some strongly desmin-positive (red) cells also
appearedonthevesselsproutsandtipcells(yellowarrowand
enlarged region shown separately in Figure 4(c)) indicative
of supporting the formation and guidance of new vessels.
In contrast, α-SMA immunoreactivity was strong in both
morphine- and PBS-treated tumors without any signiﬁcantJournal of Oncology 5
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Figure 3: Morphine stimulates tumor angiogenesis. C3TAG mice at 3 months of age were subcutaneously injected with morphine at
0.5mg/Kg/d for 2wks, and the dose was escalated every two weeks to 0.75mg/Kg/d, 1.0mg/Kg/d, 1.25mg/Kg/d, and 1.5mg/Kg/d, or with
PBS, for a period of seven weeks. Sections of tumors larger than 1cm × 0.5cm were immunostained with anti-CD31-FITC, followed by
morphometric analysis to quantify diﬀerent parameters speciﬁc to tumor angiogenesis. (a) CD31-positive pixels indicate total pixels for
CD31 immunostaining per image. (b) Length suggests the total length of vessels per image. (c) Ends denote the number of vessels per image.
(d)Nodessuggestthenumberofbranchpointsinanimage.Eachbarrepresentsmean ±SEMofsectionsfr omﬁ v ediﬀerenttumorsobtained
from 5 diﬀerent mice per treatment.
diﬀerence between the two treatment groups (Figures 4(a)
and 4(b)). Notably, all a-SMA immunoreactivity colocalized
with vascular endothelium.
3.5. Increased Expression of Vascular PDGFR-β Immunore-
activity in Tumors of Mice Treated with Morphine. Tumor
sections of mice treated with morphine show strong costain-
ing of PDGFR-β in association with endothelium, which
appears orange due to the overlaying of red and green images
of PDGFR-β and CD31, respectively (Figure 5(a)). Quan-
titatively also vessel-associated PDGFR-β immunoreactivity
was signiﬁcantly higher in morphine as compared to PBS-
treated mouse tumors (Figure 5(b)). Most of the PDGFR-
β immunoreactivity colocalized uniformly with vessels and
in the area surrounding the vasculature (red arrows) in
morphine treated mice. In contrast, in PBS-treated mice,
most of the PDGFR-β immunoreactivity colocalized with
nonvascular cells, likely with tumor cells. Of note, speciﬁc6 Journal of Oncology
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Figure 4: Morphine stimulates vessel-associated Desmin expression in mouse tumors. C3TAG mice were treated with morphine or PBS as
described in Figure 3 and the methods. (a) Upper row shows tumor sections stained with anti-CD31 for vasculature (green) and desmin
(red). Morphine-treated tumors show strong desmin (red) staining associated with tumor endothelium (green) as well as independent of
vasculature (magenta arrow). Orange staining suggests an overlap between red and green staining for desmin and vasculature, respectively.
Lower row shows strong costaining of α-smooth muscle actin (SMA, red) with CD31 (green), in both PBS and morphine-treated mice
tumors. Magniﬁcation ×150. Each image represents 5 diﬀerent tumors from 5 diﬀerent mice per treatment. (b) Ratios of desmin to CD31-
and α-SMA to CD31-immunoreactive pixels are shown. A signiﬁcant diﬀerence is observed in desmin/CD31 ratio between morphine and
PBS treatment but not in α-SMA/CD31 ratio. Each bar represents mean ± SEM of immunoreactive pixels from ﬁve tumors (3 diﬀerent
sections of each tumor) obtained from 5 diﬀerent mice per treatment. (c) Enlargement of area shown with yellow arrow in (a) for
CD31/desmin staining in morphine-treated mice. It shows colocalization of desmin staining in the sprouting endothelial cell and in the
tip cells.
colocalization of PDGFR-β was seen on vascular sprouts
(orange arrows) and at vessel branch points, in PBS group.
Thus,itappearsthatinthetumorsofthesemice,PDGFR-βis
associated with vessel branching and sprouts, whereas mor-
phine treatment increases endothelium-associated pericyte
density and pericyte coverage of vasculature.
4. Discussion
Clinically used doses of morphine/opioids act on endothe-
lium and tumor cells resulting in tumor progression in vitro
and in vivo experimental studies [18, 21, 22, 29–31]. Signi-
ﬁcantly higher expression of MOR on human lung cancerJournal of Oncology 7
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Figure 5: Morphine stimulates vessel-associated PDGFR-β expression in mouse tumors. C3TAG mice were treated with morphine or PBS
as described in Figure 3 and the methods. (a) Tumor sections were immunostained with anti-CD31 (green) and anti-PDGFR-β (red). Vas-
culature from morphine-treated mouse tumors shows strong costaining for PDGFR-β, whereas PDGFR-β staining is predominantly
observed in nonvascular compartments of PBS-treated mouse tumors. Vessel-associated PDGFR-β is observed only near the branch points
of vasculature in PBS-treated group (orange arrows). Each image represents 5 diﬀerent tumors from 5 diﬀerent mice per treatment. Magni-
ﬁcation ×900. (b) Ratios of PDGFR-β to CD31, immunoreactive pixels are shown. A signiﬁcant diﬀerence is observed in PDGFR-β/CD31
ratio between morphine and PBS treatment. Each bar represents mean ± SEM of immunoreactive pixels from ﬁve tumors (3 diﬀerent sec-
tions of each tumor) obtained from 5 diﬀerent mice per treatment.
tissue as compared to nonmalignant tissue in the same organ
complements this activity of morphine [21–23]. Therefore,
this study was undertaken to examine if pericytes were dir-
ectly or indirectly inﬂuenced by clinically relevant doses of
morphine.WeobservedthatmorphinestimulatedPDGF-BB
secretion by endothelial cells, a critical mediator of endo-
thelial-pericyte crosstalk, thus indirectly inﬂuencing pericyte
activity. Morphine also activated PDGFR-β signaling and
MAPK/ERK phosphorylation on human pericytes. These
activities of morphine on endothelial cells and pericytes cor-
relate with an increase in angiogenesis, vessel associated-des-
minand-PDDGFR-β expressingpericytesintransgenicmice
with breast cancer. Our observations on morphine-induced
vascular-pericyte interaction may have implications upon
the eﬀectiveness of antiangiogenic therapy.
PDGF-BB plays a central role in the recruitment and
growth of pericytes and in endothelial-pericyte interaction
in a paracrine manner [5, 13]. In this relationship, endothe-
lial cells secrete PDGF-BB, which acts upon the pericytes
and progenitor cells and recruits them to the endothelium.
Increased secretion of PDGF-BB by HUVEC when stimu-
lated with 0.1 and 1μM morphine demonstrates that mor-
phine plays a salutary role in HUVEC-pericyte interaction.
However, 1mM morphine did not have an eﬀect on PDGF-
BB secretion by HUVEC. It is noteworthy that in patients
treatedwitharangeofmorphinedosesfordiverseconditions
including cancer, morphine concentration ranged between
2nMand3.5μM in the plasma/serum [27, 28], which are in
therangeof0.1and1μMconcentrationshowingstimulation
of PDGF-BB secretion by HUVEC. The 1mM concentration
of morphine is highly unlikely to be present in the plasma of
patients, because an extremely high dose of morphine will be
required to achieve this plasma concentration, which in turn
m a yh a v es e v e r es i d ee ﬀects and therefore not used clinically.
We demonstrated earlier that 1mM morphine was cytotoxic
to HDMEC [18], and in the present study, we found that
HUVECs incubated with 1mM morphine for 48h were not
alive. Our observation of PDGF-BB secretion by HUVEC in
this study is further supported by an increase in expression
of PDGF-BB in HBMEC by 10−7M morphine, but not by
10−5M morphine [15]. Together, these data suggest that cli-
nically relevant dose of morphine has a stimulatory eﬀect on
PDGF-BB production by endothelial cells, which can act in
anautocrineandparacrinemannerviaPDGFR-βtopromote
angiogenesis and pericyte growth and recruitment.
PDGF-BB is known to activate PDGFR-β and several
downstream signaling pathways that promote cell prolifer-
ation, survival, and diﬀerentiation, including MAPK/ERK
and STAT3 [14, 32, 33]. We found that morphine coactivates
VEGFR2 and PDGFR-β in mouse retinal microvascular
endothelial cells (mRECs) which immunoprecipitated with
MOR[16].Ourearlierstudiesalsoshowedmorphine-induc-
ed MAPK/ERK, Stat3, and Akt phosphorylation in mREC
and HDMEC [16, 18]. In HBMECs, also morphine activat-
ed MAPK/ERK and PKB/Akt phosphorylation [15]. More
recently, we observed that morphine coactivates PDGFR-β
signaling in kidney mesangial cells in vitro and in vivo [17].
MOR silencing on kidney mesangial cells led to a signiﬁcant
decrease in morphine-induced phosphorylation of PDGFR-
β, MAPK/ERK, Stat3, and PKB/Akt, suggestive of MOR-
PDGFR-β crosstalk. This is highly signiﬁcant considering
thatMORagonistdrugsincludingmorphineareusedtotreat
pain in cancer and that PDGFR-β signaling is involved in
pericyte growth and recruitment. Our observations herein
t h a tm o r p h i n ea c t i v a t e sP D G F R - β and MAPK/ERK phos-
phorylation in pericytes to the same extent as that induced8 Journal of Oncology
by PDGF-BB suggest that morphine may increase pericyte
recruitment to the endothelium and also increase tumor
angiogenesis.
Consistent with morphine-induced secretion of PDGF-
BB by HUVEC and activation of PDGFR-β and MAPK/ERK
signaling in pericytes, we observed increased angiogenesis in
thetumorsofC3TAGmicetreatedwithmorphineusingclin-
ically relevant doses. Morphine-induced tumor angiogenesis
is in agreement with morphine-induced angiogenesis in vitro
andinvivo and promotion of breastand lung tumors in mice
[18–22]. Morphine-induced angiogenesis was replete with
excessive vessel branching and a signiﬁcantly larger number
of vessels, typical of tumor angiogenesis. These data demon-
strate that morphine promotes angiogenesis in a breast
cancermodel,whichrecapitulatestheevolutionaryspectrum
of human breast cancer. Together, the promotion of angi-
ogenesis and PDGF-BB/PDGFR-β induced endothelial-peri-
cyte interaction promoted by morphine may inﬂuence anti-
angiogenic therapy.
Increased tumor angiogenesis in morphine-treated mice
was accompanied by increased vessel-associated desmin-ex-
pressing pericytes, but not α-SMA-expressing pericytes. It is
believed that α-SMA is not expressed on pericytes associated
with normal capillaries, which express desmin, while vSMCs
on arterioles and pericytes on venules express desmin as well
asα-SMA[34,35].Ontheotherhand,α-SMAissuggestedto
be a marker of pericytes [36]. Irrespective of the treatment,
all tumor sections showed a strong expression of α-SMA on
tumor vessels. It is therefore likely that α-SMA is strongly ex-
pressed on certain type of vessels in this tumor model, which
appear to be similar to arterioles and venules and are not
inﬂuenced by morphine. Notably, strong desmin immunore-
activityintumorsofmorphine-treatedmicecolocalizedwith
endothelial sprouts and tip cells and in close proximity to
endothelial cells. This is an indication of increased pericyte
diﬀerentiation and recruitment induced by morphine in the
vicinity of endothelium. Similarly, cells expressing PDGFR-β
increasingly colocalized with vasculature in morphine group
and in close vicinity to endothelium, further demonstrating
increasedpericyterecruitmentandvascularcoverage.Indeed
increased PDGFR-b signaling leads to increased pericyte
coverageofthevasculature[14].Interestingly,inPBS-treated
mice, vessel-associated PDGFR-β-expressing pericytes were
few, and were sparsely located at vessel branch points and
on the vascular sprouts. Appreciably high PDGFR-β expres-
sionwasobservedonnonendothelialcells,perhapsontumor
cells, in PBS-treated mice. Increased microvessel density and
thicker PDGFR-β-expressing pericyte coverage were asso-
ciated with highly metastatic human KM12SM colon can-
cer cecal tumors in nude mice as compared to low meta-
static KM12C cell tumors [37]. Therefore, increased vessel-
associated pericyte coverage in tumors of morphine-treat-
ed mice in this study complements increased metastases
observed by us in subcutaneous SCK breast tumors in A/J
mice [19]. It is likely that morphine inﬂuences tumor angio-
genesis, progression, and metastases by stimulating endo-
thelial-pericyte interaction and increased pericyte recruit-
ment and coverage of vasculature, thus increasing resistance
to antiangiogenic therapy by limiting the accessibility of
drugs to the endothelium on one hand and promoting angi-
ogenesis on the other.
While using anti-angiogenic therapy, contribution of
opioids (if coadministered) to the therapeutic outcomes re-
quires consideration. To date, there are no clinical data on
theeﬀectofmorphine oncancerprogressionandmetastases.
However, OR antagonist naltrexone inhibited ovarian cancer
progression in mice [38] and improved the outcome of cis-
platin therapy in ovarian cancer [39]. Inhibition of advanced
nonmetastatic and metastatic pancreatic cancer was also
reported in patients receiving low-dose naltrexone with
an antioxidant therapy with α-lipoic acid [40]. Morphine-
induced PDGF-BB expression in HBMEC was inhibited by
naltrexone [15], suggestive of an OR-mediated mechanism.
Furthermore, a peripherally only acting MOR antagonist,
methylnaltrexone, inhibited opioid-induced angiogenesis
[20]. Therefore, coadministration of peripherally acting
MOR antagonists that do not compromise morphine anal-
gesia may improve the outcome of anti-angiogenic therapy.
In conclusion, we show that morphine stimulates PDGF-
BB secretion by endothelial cells and activates PDGFR-β
andMAPK/ERKsignalinginpericytes,thusmediatingendo-
thelial-pericyte interaction. This cellular activity of mor-
phinecorrelateswithincreasedangiogenesisrepletewithper-
icyte recruitment and coverage of tumor vasculature. Thus,
morphine treatment may inﬂuence the eﬀectiveness of anti-
angiogenic drugs.
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